Oxaliplatin Analogues with Carboxy Derivatives of Boldine with Enhanced Antioxidant Activity

Table 2

Inhibitory concentration (IC₅₀) of compounds L5, L6, 1, and 2 compared to oxaliplatin toward two human tumor cell lines (MCF-7 and HT-29) and one nontumor cell line (CCD-841).

Compound	IC50 (M)
	MCF-7	HT-29	CCD-841
L5	>100	>100	>100
L6	>100	>100	>100
1	2.8 ± 0.5	15.1 ± 2.1	11.3 ± 0.4
2	4.1 ± 0.4	5.9 ± 1.2	19.1 ± 2.0
Oxaliplatin	5.8 ± 0.8	7.7 ± 1.2	4.7 ± 0.8